Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Prock

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Developmental and Behavioral Pediatrics : JDBP|January 3, 2019
Diagnostic Uncertainty in a Complex Young Man: Autism Versus PsychosisJason Fogler, Jocelyn Kuhn, Lisa Prock, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|December 20, 2023
Developmental Delay and Behavior Challenges in an Internationally Adopted ChildLianna R Lipton, Lisa Prock, Stephen Camarata, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|August 29, 2025
Bridging the Gap in Autism Diagnosis: An Evaluation of a Novel Primary Care Training ModelJulie Bickel, Jonathan Hatoun, Margaret Fry, et al.
Molecular Therapy. Methods & Clinical Development|September 26, 2022
GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapyMaya Chopra, Meera E Modi, Kira A Dies, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 12, 2019
Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disordersSiddharth Srivastava, Jamie A Love-Nichols, Kira A Dies, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 31, 2020
Correction: Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disordersSiddharth Srivastava, Jamie A Love-Nichols, Kira A Dies, et al.
Expert Review of Neurotherapeutics|May 4, 2026
Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndromeHannah M Rea, Julia T Mattson, Vardan Arutiunian, et al.
SAGE Open Medicine|November 1, 2024
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndromeDragana Protic, Elizabeth Breeze, Guadalupe Mendoza, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Developmental and Behavioral Pediatrics : JDBP|January 3, 2019
Diagnostic Uncertainty in a Complex Young Man: Autism Versus PsychosisJason Fogler, Jocelyn Kuhn, Lisa Prock, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|December 20, 2023
Developmental Delay and Behavior Challenges in an Internationally Adopted ChildLianna R Lipton, Lisa Prock, Stephen Camarata, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|August 29, 2025
Bridging the Gap in Autism Diagnosis: An Evaluation of a Novel Primary Care Training ModelJulie Bickel, Jonathan Hatoun, Margaret Fry, et al.
Molecular Therapy. Methods & Clinical Development|September 26, 2022
GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapyMaya Chopra, Meera E Modi, Kira A Dies, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 12, 2019
Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disordersSiddharth Srivastava, Jamie A Love-Nichols, Kira A Dies, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 31, 2020
Correction: Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disordersSiddharth Srivastava, Jamie A Love-Nichols, Kira A Dies, et al.
Expert Review of Neurotherapeutics|May 4, 2026
Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndromeHannah M Rea, Julia T Mattson, Vardan Arutiunian, et al.
SAGE Open Medicine|November 1, 2024
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndromeDragana Protic, Elizabeth Breeze, Guadalupe Mendoza, et al.
Pageof 1